Sabine Eichinger News Today

A prediction model can be used to identify people affected by venous thromboembolism who have only a low risk of recurrence and may not require long-term blood thinning.

In Paris hat Olivier Nataf, der Frankreich-Chef von AstraZeneca, erklärt, dass sein Unternehmen derzeit daran arbeitet, eine dritte Dosis des Impfstoffs anzubieten. In einem Interview mit BFM erklärte Nataf: "Wir könnten eventuell bei der EMA einen Antrag auf eine dritte Dosis einreichen. Aktuell arbeiten wir daran." Es gebe vielversprechende erste Ergebnisse mit Tests, die zeigen, dass durch eine dritte Dosis des Vakzins von AstraZeneca mehr Antikorper gegen SARS-CoV-2 produziert würden. A...

AstraZeneca vaccine: Are you at risk of blood clots? JCVI issues new advice

Making sense of rare, possibly related adverse events after vaccination can be notoriously tricky, but in this case, U.S. health officials have a blueprint.

The Blood-Clot Problem Is Multiplying Roxanne Khamsi © Provided by The Atlantic DeAgostini / Getty / Katie Martin / The Atlantic For weeks, Americans looked on as other countries grappled with case reports of rare, sometimes fatal blood abnormalities among those who had received the AstraZeneca vaccine against COVID-19. That vaccine has not yet been authorized by the FDA, so restrictions on its use throughout Europe did not get that much attention in the United States. But Am...

Scientific American Researchers are searching for possible links between unusual clotting and the Oxford-AstraZeneca coronavirus vaccine Advertisement The very rare occurrence of a mysterious blood-clotting disorder among some recipients of the Oxford–AstraZeneca COVID-19 vaccine has researchers scrambling to uncover whether and how the inoculation could trigger such an unusual reaction. After weeks of investigation, the European Medicines Agency (EMA) announced on 7 April that there is a pos...